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770oxidative step in the conversion of
clopidogrel into its active metab-
olite and may therefore increase
clopidogrel biotransformation (5).
This is supported by pharma-
codynamic studies, which have
shown, with some exception (6),
that cigarette smoking enhances
clopidogrel-induced platelet in-
hibitory effects (7–12). These
pharmacodynamic ﬁndings may
explain the observations from
large-scale clinical trials demon-
strating that, among clopidogrel-
treated patients, smokers havea higher relative clinical beneﬁt compared with nonsmokers
(13–19). However, to date, such a “smoker’s paradox” has
been assessed only in patients requiring dual antiplatelet
therapy (DAPT) with aspirin and clopidogrel, and whether
smoking impacts clinical outcomes in patients with athero-
sclerotic disease manifestations requiring a single antiplatelet
agent for secondary prevention of ischemic events remains
unknown.
The CAPRIE (Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events) trial is the only large-scale head-
to-head clinical investigation comparing clopidogrel versus
aspirin for secondary prevention in patients with various
atherosclerotic disease manifestations (20). The trial showed
clopidogrel to be modestly, and statistically signiﬁcantly,
more effective in reducing ischemic outcomes than aspirin,
with a favorable safety proﬁle. The objectives of the present
analysis were 2-fold: ﬁrst, to evaluate the relationship
between smoking status and clinical outcomes in the ove-
rall CAPRIE study population; and second, to investigate
the differential effects of clopidogrel or aspirin therapy
according to smoking status.
Methods
The design, methods, and primary results of the CAPRIE
trial have been reported previously (20). In brief, CAPRIE
was a randomized, multicenter, blinded trial that compared
the efﬁcacy of clopidogrel (75 mg once daily) and aspirin
(325 mg once daily) in reducing the risk of the outcome
event cluster of ischemic stroke, myocardial infarction (MI),
or vascular death in a population of patients with athero-
sclerotic vascular disease. The study population comprised
subgroups of patients with either recent ischemic stroke,
recent MI, or symptomatic peripheral artery disease. After
a mean follow-up of 1.91 years, clopidogrel was more
effective in reducing ischemic outcomes than aspirin (5.32%
vs. 5.83%; p ¼ 0.043). For the purpose of the present
analysis, the impact of smoking status on outcomes was
evaluated in the overall study population. In addition, the
differential treatment effect (interaction) of clopidogrel
versus aspirin according to smoking status was alsoevaluated. Ischemic events were deﬁned consistent with the
primary efﬁcacy endpoint of the CAPRIE trial and included
the outcome event cluster of ischemic stroke, MI, or vascular
death, whichever occurred ﬁrst. In addition to the compo-
nents of the primary endpoint, a secondary efﬁcacy endpoint
assessed was death from any cause. Smoking status was
ascertained only at a single time at the moment of enroll-
ment, and was evaluated both as collected (never smokers, ex-
smokers, and current smokers) and by combining never
smokers/ex-smokers versus current smokers. A safety
endpoint was also considered, and CAPRIE bleeding events
were deﬁned as any bleeding disorder, as previously described
(20,21). Outcomes reported were validated by the central
validation committee of the trial.
Statistical analysis. Data are presented as numbers and
frequencies for categorical variables and as means  SD for
continuous variables. All data analyses were performed on
the intention-to-treat population including all patients who
were randomized. Baseline characteristics were compared
with the chi-square test for categorical variables and analysis
of variance for continuous variables. The effect of smoking
status on ischemic events was evaluated using a Cox pro-
portional hazards model, and p values were calculated using
a log-rank test. For the overall population, the model was
stratiﬁed by qualifying condition. Tests of interaction
between smoking status and study treatment were calculated
using the Cox proportional hazards model including treat-
ment, smoking status (as a categorical variable), and the
interaction; also included in the adjusted model are the
covariates detailed in the following text. To take into account
any imbalances in baseline variables, analyses were repeated
using multivariable Cox proportional hazards model, adjust-
ing for treatment, race, diabetes, hypercholesterolemia,
congestive heart failure, cardiomegaly, atrial ﬁbrillation, stable
angina, unstable angina, previous MI, transient ischemic
attack, reversible ischemic neurological deﬁcit, previous
ischemic stroke, intermittent claudication, and leg amputa-
tion (these variables were selected on the basis of a previous
multivariable analysis) (22), and also for age, sex, and body
mass index. The effect of smoking status and treatment on
bleeding disorders was evaluated using a logistic regression
model, and groups were compared using a chi-square test.
A 2-tailed p value of <0.05 was considered to indicate
a statistically signiﬁcant difference for all of the analyses per-
formed. Statistical analysis was performed using SAS version
9.2 software (SAS Institute, Cary, North Carolina).Results
Study population. A total of 19,185 patients were
randomized in the CAPRIE trial. Smoking status was
ascertained only at the moment of enrollment and recorded
in all except 1 patient who was excluded from the present
analysis. Of the 19,184 patients evaluated, 5,668 (29.5%)
were current smokers, 9,381 (48.9%) were ex-smokers,
and 4,135 (21.6%) never smokers. Compared with
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771never-smokers, current smokers were younger, more
frequently male, and more likely to have peripheral artery
disease, but less likely to have recent ischemic stroke as
qualifying conditions. Current smokers were also less likely
to have a history of hypertension, diabetes mellitus, atrial
ﬁbrillation, stable angina, cardiomegaly, and congestive heart
failure. Baseline demographics and clinical characteristics
stratiﬁed according to smoking status (current smokers vs.
the combined group of ex-smokers and never smokers) and
treatment are shown in Table 1.
Effect of smoking status in the overall study population.
In the overall population, current and ex-smokers had
a numerically lower rate of ischemic events (primary efﬁ-
cacy endpoint) compared with patients who never smoked:
9.5%, 9.8%, and 12.0%, respectively (p ¼ 0.30). However,
after adjustment for baseline characteristics, current
smokers had an increased risk of ischemic events compared
with patients who never smoked (hazard ratio [HR]: 1.24
[95% conﬁdence interval (CI): 1.08 to 1.42]) and to ex-
smokers (HR: 1.32 [95% CI: 1.18 to 1.47]), achieving
statistical signiﬁcance (p < 0.001). Both unadjusted and
adjusted HRs for the overall population and the study
subgroups (patients with recent ischemic stroke, recent MI,
or symptomatic peripheral artery disease) are reported
in Table 2.Table 1 Baseline Demographic Data and Clinical Characteristics Str
Aspirin
Current Smokers
(n ¼ 2,860)
Clopidogrel
Current Smokers
(n ¼ 2,808)
Age, yrs 58.6  10.9 58.3  10.8
Male 2,174 (76.0) 2,145 (76.4)
BMI, kg/m2 25.9  4.4 25.9  4.3
Race
Caucasian 2,718 (95.0) 2,665 (94.9)
Black 92 (3.2) 81 (2.9)
Asian 13 (0.5) 15 (0.5)
Other 37 (1.3) 47 (1.7)
Risk factors
Hypertension 1,225 (42.8) 1,187 (42.3)
Diabetes mellitus 451 (15.8) 425 (15.1)
Dyslipidemia 1,132 (39.6) 1,156 (41.2)
Medical history
Stable angina 510 (17.8) 525 (18.7)
Unstable angina 207 (7.2) 208 (7.4)
Atrial ﬁbrillation 56 (2.0) 87 (3.1)
Cardiac surgery 142 (5.0) 157 (5.6)
Other cardiac arrhythmia 242 (8.5) 246 (8.8)
Cardiac valve disease 79 (2.8) 81 (2.9)
Cardiomegaly 83 (2.9) 108 (3.8)
Congestive heart failure 110 (3.8) 116 (4.1)
Qualifying condition
Ischemic stroke 719 (25.1) 708 (25.2)
Peripheral artery disease 1,235 (43.2) 1,232 (43.9)
Myocardial infarction 906 (31.7) 868 (30.9)
Values are mean  SD or n (%).
BMI ¼ body mass index.Similar results were obtained when analyzing smoking
status as a dichotomous variable. Current smokers had
a numerically lower rate of the primary efﬁcacy endpoint
compared with ex-smokers/never-smoked patients, which
did not reach statistical signiﬁcance (9.5% vs. 10.5%, HR:
0.99 [95% CI: 0.89 to 1.09]; p ¼ 0.82). However, in the
adjusted model, current smokers had an enhanced risk of
ischemic outcomes compared with the combined group of
ex-smokers/never-smoked subjects (HR: 1.30 [95% CI: 1.17
to 1.44]; p < 0.001).
Bleeding disorders occurred in 8.6% of current smokers,
9.7% of ex-smokers, and 9.1% of never-smoked patients
(p ¼ 0.07). When evaluating smoking status as a dichoto-
mous variable, current smokers had a lower rate of bleeding
events compared with ex-smokers/never-smoked subjects
(8.6% vs. 9.6%; odds ratio [OR]: 0.89 [95% CI: 0.80 to
0.99]; p ¼ 0.04). In the adjusted model, the ratio was
inverted, indicating that current smokers had a signiﬁcantly
increased risk of bleeding events compared with patients
who had never smoked (OR: 1.23 [95% CI: 1.04 to 1.46];
p ¼ 0.02) and similar when compared with ex-smokers
(OR: 0.93 [95% CI: 0.83 to 1.05]; p ¼ 0.25). No differ-
ence was seen between current smokers and the combined
group of ex-smokers/never-smoked patients (OR: 1.01
[95% CI: 0.90 to 1.13]; p ¼ 0.93).atiﬁed According to Smoking Status and Treatment
p Value
Aspirin
Ex/Never Smokers
(n ¼ 6,726)
Clopidogrel
Ex/Never Smokers
(n ¼ 6,726) p Value
0.3933 64.2  10.7 64.1  10.8 0.8294
0.7404 4,731 (70.3) 4,804 (70.8) 0.5992
0.8158 26.7  4.4 26.7  4.4 0.7273
0.5564 0.0025
6,378 (94.8) 6,415 (94.5)
169 (2.5) 210 (3.1)
65 (1.0) 35 (0.5)
114 (1.7) 130 (1.9)
0.6698 3,679 (54.7) 3,793 (55.9) 0.1738
0.5092 1,510 (22.5) 1,494 (22.0) 0.5318
0.2232 2,845 (42.3) 2,770 (40.8) 0.0762
0.3997 1,561 (23.2) 1,575 (23.2) 0.9862
0.8063 617 (9.2) 629 (9.3) 0.8561
0.0062 337 (5.0) 331 (4.9) 0.7161
0.2917 566 (8.4) 623 (9.2) 0.1188
0.6881 734 (10.9) 821 (12.1) 0.0318
0.7809 282 (4.2) 305 (4.5) 0.3935
0.0489 333 (5.0) 361 (5.3) 0.3355
0.5836 414 (6.2) 433 (6.4) 0.5947
0.8084 0.8961
2,479 (36.9) 2,525 (37.2)
1,994 (29.6) 1,991 (29.3)
2,253 (33.5) 2,274 (33.5)
Table 2
Summary of Patients With Ischemic Events and Unadjusted and Adjusted HRs for the Primary Efﬁcacy Endpoint
According to Smoking Status
Never Smokers
(n ¼ 4,135)
Ex-Smokers
(n ¼ 9,381)
Current Smokers
(n ¼ 5,668)
Unadjusted HR
(95% CI)
Adjusted HR*
(95% CI)
Overall (N ¼ 19,184) 496 (12.0) 921 (9.8) 541 (9.5) 0.92 (0.82–1.03) 0.94 (0.83–1.06)
0.93 (0.82–1.06) 1.24 (1.08–1.42)
1.02 (0.91–1.13) 1.32 (1.18–1.47)
Ischemic stroke (n ¼ 6,431) 296 (13.4) 383 (13.7) 215 (15.1) 1.01 (0.87–1.18) 0.98 (0.83–1.15)
1.11 (0.93–1.32) 1.34 (1.10–1.62)
1.09 (0.93–1.29) 1.37 (1.15–1.63)
Myocardial infarction (n ¼ 6,301) 139 (10.3) 290 (9.1) 143 (8.1) 0.87 (0.71–1.07) 1.00 (0.81–1.24)
0.78 (0.62–0.98) 1.18 (0.91–1.52)
0.89 (0.73–1.09) 1.18 (0.96–1.45)
Peripheral artery disease (n ¼ 6,452) 61 (10.6) 248 (7.3) 183 (7.4) 0.65 (0.49–0.86) 0.71 (0.53–0.96)
0.68 (0.51–0.91) 1.02 (0.74–1.41)
1.05 (0.87–1.28) 1.43 (1.18–1.75)
Values are n (%). In the Unadjusted and Adjusted HR columns, the ﬁrst hazard ratio (HR) is for ex-smokers versus never smokers, the second hazard ratio is for current smokers versus never smokers, and the
third hazard ratio is for current smokers versus ex-smokers. *Model adjusted for treatment, age, sex, body mass index, race, diabetes, hypercholesterolemia, congestive heart failure, cardiomegaly, atrial
ﬁbrillation, stable angina, unstable angina, previous myocardial infarction, transient ischemic attack, reversible ischemic neurological deﬁcit, previous ischemic stroke, intermittent claudication, and leg
amputation.
CI ¼ conﬁdence interval.
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772Effect of smoking status on study treatment: clopidogrel
versus aspirin. In aspirin-treated patients, the unadjusted
analysis showed no signiﬁcant difference according to
smoking status (current smokers vs. ex-smokers/never-
smoked subjects) in the overall population (10.8% vs.
10.6%, HR: 1.11 [95% CI: 0.97 to 1.27]; p ¼ 0.14).
However, in the adjusted model, current smokers had
a higher risk of ischemic outcomes (HR: 1.39 [95% CI: 1.20
to 1.60]; p < 0.001), an effect that was consistent among all
qualifying conditions. Similarly, the impact on ischemic
outcomes in clopidogrel-treated patients was not observed
in the unadjusted model (8.3% vs. 10.4%, HR: 0.87 [95%
CI: 0.75 to 1.01]; p ¼ 0.07), but it reached signiﬁcance
in the adjusted analysis (HR: 1.19 [95% CI: 1.02 to 1.39];
p ¼ 0.03).
A signiﬁcant interaction between study treatment and
smoking status was found (p ¼ 0.01 for interaction) when
evaluated as a dichotomous variable (current smokers vs.
ex-smokers/never-smoked patients). In particular, clopidogrel-
treated patients had no reduction in the incidence of the
primary efﬁcacy outcome compared with aspirin-treated
patients in the combined group of ex-smokers/never-
smoked patients (10.4% vs. 10.6%; HR: 0.99 [95% CI:
0.89 to 1.10]; p ¼ 0.73), whereas patients treated with
clopidogrel in the current smoker group had a signiﬁcantly
lower rate of ischemic events (8.3% vs. 10.8%; HR: 0.76
[95% CI: 0.64 to 0.90]; p ¼ 0.001) than aspirin-treated
patients (Fig. 1). This trend toward a lower risk of
ischemic events among clopidogrel-treated subjects was
observed in all qualifying conditions (recent ischemic stroke:
14.0% vs. 16.1%, HR: 0.88 [95% CI: 0.67 to 1.16]; recent
MI: 7.4% vs. 8.7%, HR: 0.88 [95% CI: 0.63 to 1.22];
and peripheral artery disease: 5.7% vs. 9.1%, HR: 0.60
[95% CI: 0.44 to 0.81]). The beneﬁt of the clopidogrel-
treated current smokers subgroup compared with the
other 3 subgroups (clopidogrel-treated ex-smokers/neversmoked, aspirin-treated current smokers, and aspirin-
treated ex-smokers/never smoked) was observed during the
entire study follow-up (Fig. 2A). Among current smokers,
in addition to the beneﬁt observed in the combined primary
efﬁcacy endpoint, clopidogrel was associated with a reduc-
tion in MI, vascular death, or death from any cause
compared with aspirin, with the interaction mainly due to
the difference in the rates of vascular death (Fig. 3).
When evaluating smoking status as a variable with
3 categories (current smokers, ex-smokers, and never
smokers), a signiﬁcant interaction (p < 0.01) with study
treatment for the primary efﬁcacy endpoint was observed
in the overall population due to no observed efﬁcacy in
ex-smokers (clopidogrel vs. aspirin: 8.3% vs. 10.8% in current
smokers, HR: 0.76 [95% CI: 0.64 to 0.90], p ¼ 0.002;
10.1% vs. 9.5% in ex-smokers, HR: 1.10 [95% CI: 0.97 to
1.26], p ¼ 0.14; 10.9% vs. 13.1% in patients who never
smoked, HR: 0.79 [95% CI: 0.66 to 0.94]; p < 0.01).
No interaction between smoking status and study treat-
ment was observed for bleeding events when considering
the variable smoking status with 3 categories (current
smokers, ex-smokers, and never smokers) or dichotomous
(current smokers vs. ex-smokers/never-smoked patients):
p ¼ 0.35 and p ¼ 0.73 for interaction, respectively. The
incidence of bleeding events in the 4 subgroups of subjects
evaluated according to smoking status and treatment
(clopidogrel-treated current smokers, clopidogrel-treated
ex-smokers/never smokers, aspirin-treated current smokers,
and aspirin-treated ex-smokers/never smokers) was similar,
as illustrated in Figure 2B.
Discussion
The present analysis of the CAPRIE trial showed that: 1)
current smokers, despite being younger and with fewer
comorbidities, presented in the adjusted model with an
Figure 1 Ischemic Events According to Smoking Status and Study Treatment
Percentage of patients with ischemic events according to smoking status (never/ex-smokers vs. current smokers) and study treatment (aspirin vs. clopidogrel) is shown.
HR ¼ hazard ratio.
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773increased risk of long-term ischemic events; 2) among
current smokers, clopidogrel therapy achieved a reduction in
ischemic events, whereas no difference between aspirin and
clopidogrel treatment was observed in the combined group
of ex-smokers/never smokers; and 3) no signiﬁcant inter-
action was seen between treatment and smoking habit for
bleeding events. Although smoking cessation represents the
optimal healthcare goal, these ﬁndings suggest that clopi-
dogrel may offer greater ischemic protection and potentially
be preferred over aspirin for smokers with stable athero-
sclerotic vascular disease and requiring a single antiplatelet
drug regimen. Indeed, the availability of clopidogrel in
a generic formulation with contained costs, which in the past
had limited its more broad-scale use, makes this an
appealing treatment option in subsets of patients in which
clopidogrel may improve outcomes when compared with
aspirin.
Smoking is an established major risk factor for all-cause
and cardiovascular mortality, as well as for ischemic and
bleeding outcomes, and smoking cessation is a Class I
recommendation (Level of Evidence: A) for secondary
prevention in patients with atherosclerotic vascular disease
(23). Although the optimal healthcare goal is to reinforce the
importance of smoking cessation, this is not achieved in
many patients, as also reﬂected by the slowing in the decline
in adult smoking (24). These observations underscore the
importance of deﬁning more-effective secondary prevention
treatment strategies for patients who continue to smoke and
thus remain at increased risk for ischemic recurrences.
DAPT with aspirin and clopidogrel represents the most
broadly utilized treatment for patients presenting with an
acute coronary syndrome (ACS) or undergoing percutaneouscoronary intervention (PCI). Despite having increased
rates of adverse events, smokers have been shown to have
a higher relative clinical beneﬁt of DAPT compared with
nonsmokers (13–19). Importantly, for patients requiring
DAPT, more-potent antiplatelet treatment strategies (e.g.,
prasugrel, ticagrelor) are currently available, and may
therefore be considered in patients requiring more effective
platelet blockade because of their high-risk proﬁle (25,26).
These agents have a more favorable pharmacokinetic and
pharmacodynamic proﬁle compared with clopidogrel, and
outcomes of patients treated with these agents are not
affected by smoking (6,27). This is supported also in the
recently reported PARADOX (Inﬂuence of Smoking Status
on Prasugrel and Clopidogrel Treated Subjects Taking
Aspirin and Having Stable Coronary Artery Disease) trial,
which showed that the antiplatelet efﬁcacy of clopidogrel is
reduced in nonsmokers, whereas prasugrel-mediated platelet
inhibition is not inﬂuenced by smoking status (28). In
addition, in the large-scale TRILOGY ACS (Targeted
Platelet Inhibition to Clarify the Optimal Strategy to
Medically Manage Acute Coronary Syndromes) clinical trial
that randomized ACS patients not undergoing revasculari-
zation to long-term therapy with prasugrel versus clopi-
dogrel (29), there was a signiﬁcant interaction between
treatment and smoking, showing almost a 50% relative
reduction in ischemic events with prasugrel versus clopi-
dogrel treatment among smokers. Because smoking had no
signiﬁcant impact on prasugrel efﬁcacy, this differential
effect might be due to an increased risk of adverse outcomes
of smokers compared with nonsmokers among clopidogrel-
treated patients (30). Because smokers have an increased
density of P2Y12 receptors on the platelet surface (31),
Figure 2 Kaplan-Meier Curves of Ischemic and Bleeding Events Stratiﬁed According to Smoking Status and Study Treatment
(A) The cumulative ischemic event rates, expressed as percentages, according to smoking status (never [Nvr]/ex-smokers [Ex] and current [Cur] smokers) and study treatment
(aspirin [ASA] and clopidogrel [Clop]). (B) The cumulative bleeding event rate, expressed as percentages, according to smoking status (never/ex-smokers and current smokers)
and study treatment (aspirin and clopidogrel).
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774this may also have played a role in the observed beneﬁt
of prasugrel over clopidogrel in this subgroup analysis (30).
Most patients with atherosclerotic manifestations do not
have a clinical indication to be on DAPT, which is
generally recommended for up to 1 year in the settings of
ACS and PCI, and the use of DAPT has been shown tobe potentially harmful outside of these clinical presenta-
tions (32). Therefore, deﬁning the optimal treatment for
patients requiring only a single antiplatelet agent, either
aspirin or clopidogrel, for secondary prevention of ischemic
events is of paramount importance. Overall, the results of
the present investigation may have practical implications
Figure 3 HRs for Cardiovascular Events
Hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for cardiovascular events in clopidogrel-versus aspirin-treated patients (adjusted model) are shown. ASA ¼ aspirin;
MI ¼ myocardial infarction.
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775for current clinical practice. In particular, one might
consider recommending clopidogrel therapy for smokers
and aspirin for nonsmokers when a single antiplatelet agent
is required in patients with atherothrombotic diseases, such
as for secondary prevention in patients with peripheral
artery disease, a prior stroke, or in those with ACS or PCI
after completing 1 year of DAPT. Further, the use of
clopidogrel must be also considered in nonsmoking,
aspirin-intolerant patients, because no other option (e.g.,
prasugrel, ticagrelor) has been tested for monotherapy. If
P2Y12 blockade is clinically superior to aspirin, as it
appears to be in clopidogrel-treated smokers, the ﬁndings
of this study also pose the question of whether mono-
therapy with the more potent P2Y12 antagonist prasugrel
or ticagrelor would be even superior to both aspirin and
clopidogrel. This concept is currently being evaluated in
the GLOBAL LEADERS (A Clinical Study Comparing
Two Forms of Anti-platelet Therapy After Stent
Implantation) trial (NCT01813435) that aims to enroll
approximately 16,000 patients from an “all-comers” pop-
ulation undergoing PCI with a drug-eluting stent with an
abluminally-coated biodegradable polymer. Patients will be
followed for 2 years after being randomized to either: 1)
a study treatment strategy of 1 month of aspirin plus
ticagrelor followed by 23 months of ticagrelor mono-
therapy; or 2) a reference treatment strategy of 12 months
of DAPT (aspirin plus ticagrelor for ACS patients; aspirinplus clopidogrel for elective patients) followed by 12
months of aspirin monotherapy.
CAPRIE is the only large-scale investigation to our
knowledge to assess differences in safety and efﬁcacy
between aspirin and clopidogrel monotherapy for secondary
prevention of ischemic events in patients with atherosclerotic
disease manifestations. Although clopidogrel was associated
with a favorable safety proﬁle, including bleeding and
nonbleeding side effects, and reduced ischemic event rates
compared with aspirin, a ﬁnding that was of even greater
magnitude in higher-risk subgroups, aspirin has represented
the mainstay of treatment for these patients (20,33). Indeed,
costs may have contributed to this practice pattern, given
that clopidogrel has only recently become available in
a generic formulation. Importantly, the ﬁndings of the
present investigation also suggest that the beneﬁt of clopi-
dogrel over aspirin can be attributed in part to its effect
among smokers. The greater magnitude of beneﬁt of
clopidogrel among smokers (smoker’s paradox) is likely
attributed to the more effective platelet inhibition that is
achieved in these patients, as demonstrated by the higher
rates of reperfusion observed in patients with ST-segment
elevation MI undergoing routine angiography (13), and
also consistently shown in various pharmacodynamic inves-
tigations (13–16). However, this greater effect of clopidogrel
among smokers must not be overstated, and it must not be
concluded from the results of our study that clopidogrel is
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776not effective in patients that do not currently smoke. In fact,
in the present analysis, patients who were “never smokers”
(when not combined with ex-smokers) also obtained
a beneﬁt from clopidogrel therapy compared with aspirin.
Pharmacodynamic studies have shown a broad range in the
interindividual response proﬁle among clopidogrel-treated
patients, and those who have high on-treatment platelet
reactivity have an increased risk of ischemic recurrences,
including stent thrombosis (34,35). Cigarette smoking is
a strong inducer of the activity of CYP1A2 and CYP2B6,
which are involved in the hepatic transformation of clopi-
dogrel (1,2), thus leading to an enhanced production of
its active metabolite (5). The greater clopidogrel-induced
platelet inhibition observed in current smokers compared
with nonsmokers was ﬁrst demonstrated by Bliden et al. (7)
in a cohort of patients on DAPT undergoing elective coro-
nary stenting, and later conﬁrmed in other settings (8,9),
notably showing a dose–response effect according to the
intensity of smoking (9). Although some studies have not
found an association between smoking and clopidogrel efﬁ-
cacy (6), a causal relationship between smoking and degree
of clopidogrel-induced antiplatelet effects is also supported
by the observation that the enhanced platelet inhibitory
effects among smokers diminished with smoking discontin-
uation (36). Other studies suggest that this beneﬁt may
occur in patients more likely to have reduced clopidogrel
response, based on clinical presentation (e.g., diabetic status)
or CYP1A2 polymorphisms (9,37).
In addition to a more favorable metabolism of clopidogrel
due to enhanced CYP enzymatic activity, other mechanisms
may contribute to the beneﬁt among smokers. Nicotine has
been shown to be associated with higher platelet P2Y12
receptor expression in platelet lysates compared with that of
nonsmokers (31). Therefore, it may be hypothesized that
the beneﬁt of clopidogrel over aspirin may be due to the
fact that smokers have higher platelet surface P2Y12 density,
contributing to their higher risk for recurrent events, which
can be suppressed by clopidogrel, but not by aspirin (31).
Also, smoking has been associated with less biological
efﬁcacy of aspirin, also coined “aspirin resistance,” as
determined by increased platelet reactivity and incomplete
inhibition of thromboxane biosynthesis compared with
that of smokers (38). However, in the CHARISMA (Clo-
pidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management and Avoidance) trial, randomi-
zation to clopidogrel versus placebo did not reduce the hazard
of cardiovascular events in low-risk aspirin-treated patients
in the highest quartile of urinary 11-dehydro-thromboxane
B2 levels (39).
Study limitations. The major limitation is that the present
study is a post-hoc subgroup analysis of a large-scale clinical
trial and, thus, there is potential for bias because the study
was not designed and powered for subgroup analyses.
Indeed, the more subgroup analyses of a given trial that are
performed, the more likely that a positive ﬁnding in 1 of
them may be due to the play of chance. Therefore, theresults observed in the present investigation must be
considered only hypothesis generating. For instance, the fact
that the beneﬁt observed for clopidogrel therapy among
current smokers mainly depended on the individual
endpoint of vascular death, whereas no relevant interaction
was seen for stroke or MI, urges caution with the conclu-
sions derived regarding a different clopidogrel beneﬁt
depending on smoking status. This is also in line with the
observation from the present analysis that patients who were
never smokers (when not combined with ex-smokers) also
obtained a beneﬁt from clopidogrel therapy compared with
aspirin. Further, the CAPRIE trial was published in 1996,
which may limit the clinical signiﬁcance of the present
analysis because clinical practice has evolved and differs from
standards used when patients were recruited in this trial.
However, this is the ﬁrst study to assess the impact of
smoking in patients requiring single antiplatelet therapy for
secondary prevention of ischemic events, which in addition
to the consistent ﬁndings with DAPT trials (13–16) and
the plausible biological explanations based on a multitude
of pharmacodynamic studies, is reassuring (7–12). Finally,
smoking status was based on a single determination at
enrollment that may have changed over the study period.
However, misclassiﬁcation of smoking status would more
likely have attenuated the strength of the association
between current smokers and adverse outcomes.
Conclusions
In a population of patients with stable atherosclerotic
vascular disease, smoking is associated with an increased
risk of adverse ischemic outcomes, both in aspirin- and
clopidogrel-treated patients. Current smokers treated with
clopidogrel for the secondary prevention of ischemic
recurrences had a greater reduction in events compared with
those treated with aspirin, whereas no clear beneﬁt of clo-
pidogrel over aspirin was seen in the combined group of
ex-smokers/never smokers. Although smoking cessation
represents the optimal healthcare goal, these ﬁndings sug-
gest that clopidogrel may offer greater ischemic protection
and potentially be preferred over aspirin for smokers with
stable atherosclerotic vascular disease requiring a single
antiplatelet drug.
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